Lyka Labs Ltd - Stock Valuation and Financial Performance

BSE: 500259 | NSE: LYKALABS | Pharmaceuticals & Drugs | Small Cap

Lyka Labs Share Price

105.30 -2.50 -2.32%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Lyka Labs

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

yka Labs stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
350.6 Cr.
52-wk low:
89
52-wk high:
143.5

Is Lyka Labs Ltd an attractive stock to invest in?

1. Is Lyka Labs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Lyka Labs Ltd is a average quality company.

2. Is Lyka Labs Ltd undervalued or overvalued?

The key valuation ratios of Lyka Labs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Lyka Labs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Lyka Labs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Lyka Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Lyka Labs Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Jun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -2.5%6.8%8.2%6.9%-2.4%3.1%-15.1%2.5%31.9%-0.3%-
Value Creation
Index
-1.2-0.5-0.4-0.5-1.2-0.8-2.1-0.81.3-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 69.490.576.47841.741.240.762.316480.699
Sales YoY Gr.-30.3%-15.6%2.2%-46.6%-1.2%-1.1%52.8%164%-51%-
Adj EPS -8.5-0.630.4-3.60.7-13.8-4.914-2.8-1.1
YoY Gr.-NANA-88.4%-1128.6%NA-2036.6%NANA-120%-
BVPS (₹) 21.526.33833.434.134.86.61.515.519.230.5
Adj Net
Profit
-18.3-1.36.70.8-10.12-39.4-13.940.2-8.6-4
Cash Flow from Ops. 44.329.110.320.26.818.3-11.55.876.56.9-
Debt/CF from Ops. 2.53.713.65.614.95-1228.11.710.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 1.7%14.1%25.5%-51%
Adj EPS NANANA-120%
BVPS-1.2%-10.8%43.2%24.1%
Share Price 26.5% 33.9% 64.5% 0.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Jun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
-34.9-27.81.1-11.92.1-67.2-120.2164.5-14.2-4.4
Op. Profit
Mgn %
-0.421.713.327.9-1.22.2-7.923.259.319.415.3
Net Profit
Mgn %
-26.3-1.48.71-24.34.9-96.8-22.424.5-10.7-3.7
Debt to
Equity
2.41.91.61.51.10.97.336.72.91.2-
Working Cap
Days
36929946130160263349323010124787
Cash Conv.
Cycle
40-55-54-509112962-25-67029

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 25.53%

Debt to equity has declined versus last 3 years average to 1.21

Sales growth is good in last 4 quarters at 17.91%

Return on Equity is Poor

Latest Financials - Lyka Labs Ltd.

Standalone Consolidated
TTM EPS (₹) -1.1 -1.1
TTM Sales (₹ Cr.) 98.9 106
BVPS (₹.) 30.5 21.2
Reserves (₹ Cr.) 68 37
P/BV 3.48 4.99
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 89.00 / 143.50
All Time Low / High (₹) 8.46 / 267.20
Market Cap (₹ Cr.) 351
Equity (₹ Cr.) 33.1
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Lyka Labs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *17.9516.987.125.535.125.120.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Lyka Labs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales879057784241416216481
Operating Expenses 87715056424044486765
Manufacturing Costs4323336689
Material Costs54513436222220243129
Employee Cost 1410710111012131617
Other Costs 1477775751210
Operating Profit 020822-11-3149716
Operating Profit Margin (%) -0.4%21.7%13.3%27.9%-1.2%2.2%-7.9%23.2%59.3%19.4%
Other Income 52122233233
Interest 252013178619262012
Depreciation 543664881514
Exceptional Items 1941-21-1-28-1-5-7
Profit Before Tax -715-1-11-7-55-1860-13
Tax 00000-90-4200
Profit After Tax -7150-112-55-1440-13
PAT Margin (%) -8.4%1.5%8.4%-0.2%-26.0%4.2%-135.0%-23.2%24.3%-16.5%
Adjusted EPS (₹)-3.40.62.2-0.1-3.90.6-19.3-5.013.9-4.3
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 6361677496981944459
Share Capital 23232322282829292931
Reserves 403843526870-10-241628
Minority Interest0000000000
Debt10065727340911361618271
Long Term Debt552925355791261516263
Short Term Debt4536463836121110208
Trade Payables353930282122171298
Others Liabilities 65686067862737207441
Total Liabilities 263233228242243238209197209179

Fixed Assets

Gross Block13398100939493141163172154
Accumulated Depreciation3937407131739688288
Net Fixed Assets946260868176102959066
CWIP 22273024263026241816
Investments 63636362626232323232
Inventories91379766487
Trade Receivables2529262430307101817
Cash Equivalents 72210087159
Others Assets44394034353428242732
Total Assets 263233228242243238209197209179

Cash Flow

(All Figures are in Crores.)
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 5529820718-116777
PBT -715-1-11-7-55-1860-13
Adjustment 2718322121055343831
Changes in Working Capital 7710-0-0715-12-9-21-11
Tax Paid 0-10-1001-1-10
Cash Flow From Investing Activity -25295-5-3-300-47
Capex -1428-5-5-3-3-1-1-66
Net Investments -12000000000
Others 10100001121
Cash Flow From Financing Activity -29-63-13-15-4-1620-8-63-20
Net Proceeds from Shares 000034020045
Net Proceeds from Borrowing 00010-3174280-50-46
Interest Paid -22-19-11-16-6-6-6-6-22-10
Dividend Paid 0000000000
Others -7-44-2-8-1-84-4-19-10
Net Cash Flow 2-500-108-29-7
PARTICULARSJun'14Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)-11.82.388.07-0.27-12.781.79-94.98-124.71163.37-25.69
ROCE (%)9.2811.6210.479.01-1.8-0.7-20.894.4547.25-1.02
Asset Turnover Ratio0.370.390.260.360.180.170.180.310.810.42
PAT to CFO Conversion(x)N/A291.6-INFN/A9N/AN/A1.93N/A
Working Capital Days
Receivable Days165102166109234266162483179
Inventory Days45405935715952291434
Payable Days243266372293419356359221122106

Lyka Labs Ltd Stock News

Lyka Labs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Lyka Labs on 28-Mar-2024 16:01 is ₹105.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Lyka Labs stood at ₹350.6.
The latest P/E ratio of Lyka Labs as of 28-Mar-2024 16:01 is 0.00.
The latest P/B ratio of Lyka Labs as of 28-Mar-2024 16:01 is 3.48.
The 52-week high of Lyka Labs is ₹143.5 and the 52-week low is ₹89.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Lyka Labs is ₹98.87 ( Cr.) .

About Lyka Labs Ltd

Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on  December 19, 1985.

The company is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs is committed to creating a better tomorrow for India. Maintaining a core competency in Lyophilization, allows Lyka Labs to supply Freeze Dried Drugs in sufficient quantities with the right quality. Lyka strives to manage this business in an ethical and transparent manner.

Lyka has 2 manufacturing facilities in Ankleshwar and Tarapur. There is also an R & D facility based in Chakala, Mumbai, and a corporate head office based in Andheri, Mumbai.

Plant located at Ankleshwar, Gujarat is one of the largest chemical Industrial estates in Asia. Located approx. 10 kms from the city of Bharuch, Gujarat. Ankleshwar is well connected and can be reached by road, rail or air from Mumbai, or by road and rail from Vadodara, or Ahmedabad.

Tarapur Plant is located in the MIDC Industrial Estate in Tarapur, District Thane, Maharashtra. Located approximately 80 kms from Mumbai City, and well connected by rail and road to Mumbai. 

Different business lines of the company:

  • Contract Manufacturing - Lyka undertakes manufacturing activities for a number of different companies on a Principal to Principal Basis. In most cases Lyka would undertake the entire manufacturing process, from sourcing of raw materials to manufacture to packaging, although Lyka also offers job work services where the raw materials are sourced by the client company. Their manufacturing processes are in line with world over best practices, as demonstrated by the ISO 9001:2002 Certification
  • Hospital Division - LYKA has forayed into marketing of products into hospitals/ institutions. To begin with, it has introduced a range of anti-infectives, which include systemic antimalarial, antifungal and antibacterials for serious infections. Apart from this, it has also introduced anesthetics, anti-ulcerants and steroid in parenteral dosage forms. On the anvil is the expansion of the range of the products in the above therapeutic segments as well as in the new therapeutic segments. The company also has plan to introduce products in solid dosage forms for hospitals / institutions.
  • Lyka Animal Health Care - Lyka Animal Healthcare Division within a short period has made strong presence in Indian Veterinary market with their quality innovative products. The animal healthcare division is managed and headed by veterinary professional with strong and dedicated team of field and in-house persons.
  • Generics - When generic products become available, the market competition often leads to substantially lower prices for both the original brand name product and the generic forms. Lyka markets branded generic products in the form of: -Tablets -Capsules -Ointments -Syrups Dry Powder and Liquids
  • Lyka BDR- Lyka manufactures and sells products to its Joint Venture company Lyka BDR. Lyka BDR is the largest seller of human and veterinary products in Sudan

Product range of the company includes:

  • Ampholyn Inj.  
  • Hydrolin Inj.   
  • Lyom Inj.   
  • Lypan Inj.   
  • Lypitaz Inj. 2.25g   
  • Lypitaz Inj. 4.5g   
  • Lyrab Inj.   
  • Lysunate Inj.  
  • Lysunate Tabs  
  • Lyvec Inj.   
  • Merojet Inj. 500mg   
  • Merojet Inj.1000mg   
  • Stropaz Inj.   
  • Thiolyn Inj. 500mg  
  • Thiolyn Inj.1000mg   
  • Vancolym Inj.   
  • Xolycef - SB Inj.   
  • Xolycef - TZ Inj.   
  • Xolycef Inj. 1000mg 
  • Zimtaz Inj. 

Achievements/ recognition:

  • ISO 9001:2000 certified
  • Recognized as in-house R&D Centre by Government of India, Ministry of Science & Technology, Department of Scientific and Industrial Research.
  • In 2011 the company has been conferred Certificate of Appreciation Patent Award by Pharmaceuticals Export Promotion Council.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.